Adam Koppel bought $25M of KLRA
director, owner at Kailera Therapeutics, Inc.. 1,562,500 shares at an average of $16.00, traded Apr 20, 2026, filed Apr 20, 2026.
Score components
- +15RoleDirector
- +25Trade size$25.0M at market
- +3Relative to holdingsHoldings up 7%
- +10Price context0% above the 52-week low
- +15Cluster5 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-164407, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 20, 2026 | CConversion Common Stockindirect: See footnotes | +16,875,000 | - | - | 16,875,000 | Apr 20, 2026 |
| Apr 20, 2026 | CConversion Common Stockindirect: See footnotes | +4,145,768 | - | - | 21,020,768 | Apr 20, 2026 |
| Apr 20, 2026 | POpen-market purchase Common Stockindirect: See footnotes | +1,562,500 | $16.00 | $25M | 22,583,268 | Apr 20, 2026 |
| Apr 20, 2026 | CConversion Series A-1 Preferred Stockderivativeindirect: See footnotes | -16,875,000 | $0.00 | $0 | 0 | Apr 20, 2026 |
| Apr 20, 2026 | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -4,145,768 | $0.00 | $0 | 0 | Apr 20, 2026 |
| Apr 16, 2026 | AGrant or award Stock Option (right to buy)derivative | +38,300 | $0.00 | $0 | 38,300 | Apr 20, 2026 |
Related signals
Other insiders at Kailera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 57Moderate | Kailera Therapeutics, Inc. | Rtw Investments, LP owner | $8.0M 500,000 shares | +5% | |
| 63Notable | Kailera Therapeutics, Inc. | Bain Capital Investors LLC owner | $134M 8,398,438 shares | +47% | |
| 60Notable | Kailera Therapeutics, Inc. | Bain Capital Life Sciences Investors, LLC owner | $25M 1,562,500 shares | +7% | |
| 71Notable | Kailera Therapeutics, Inc. | Andrew T. Kaplan director, owner | $134M 8,398,438 shares | +47% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.